Blumenthal-Cornyn Legislation Would Encourage More Generic and Biosimilar Competition in the Prescription Drug Market to Help Lower Costs for Patients (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today following the reintroduction of the “Affordable
In case you missed it, the Competitive Enterprise Institute (CEI) released a new video, “Pharmacy Benefit Managers and Healthcare Costs: Not a Policy Paper, Just A Thought,” explaining how pharmacy benefit companies lower health care costs. Dr. Joel Zinberg, senior
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. WHAT IS WHITE BAGGING… There’s a lot of jargon in
While debating important legislative proposals that can impact patients’ health and access to medications, the discussion should rely on solid facts and evidence. Today, we’re highlighting new reputable third-party research and analyses by economists which underscore that legislation focused on
Pharmacy benefit companies push big drug companies for price concessions through rebates. 99.6 percent of rebates get passed directly to Medicare Part D plans, and 91 percent to other health plan sponsors, like employers and unions, who use those savings
Encouraging Signs that the Insulin Affordability Battle is Improving This week, as congressional hearings focus on access to affordable insulins, it should be recognized that a multitude of market forces are working to reduce the cost of insulin products for
PBMs: Committed to Helping Patients The Critical Path Forward: Rx Policies to Reduce Patient Costs, Improve Access For America’s pharmacy benefit managers, PBMs, our core mission is to increase access to affordable prescription drugs for all Americans. But more can
The federal government spends a lot of money on prescription drugs. Medicare Part D, the program to help seniors pay for their prescription drugs, provides benefits to 45 million people and its budget for the upcoming fiscal year will exceed $90
So-called “delinking” policies continue to be discussed in Congress. Among several glaring problems — including a rejection of free market performance-based incentives that lower drug costs for consumers — if enacted, “delinking” would hand a financial windfall totaling up to
©2024 PCMA. All Rights Reserved.
